author-photo

Steven A. Limentani

Tufts University

43

Papers

5388

Citations

Citation Trend

Filter By

Papers (31) Sort By

Journal Conference Others

A phase I dose-escalation study evaluating weekly paclitaxel with neratinib and trastuzumab in women with metastatic HER2-positive breast cancer, NSABP FB-8.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (12)
Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9

2015 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (15)
Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS).

2009 Supportive Care in Cancer
Show All
- Source
- Cite
- Save
Citations (17)
Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study

2009 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (149)
Efficacy and safety of single-agent axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial

2008 Pneumologie
Show All
- Source
- Cite
- Save
Citations (1)
Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer

2008 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (12)
6551 POSTER Efficacy and safety of single-agent axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial

2007 Ejc Supplements
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II trial

2007 Clinical Lung Cancer
Show All
- Source
- Cite
- Save
Citations (43)
Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma.

2007 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib

2006 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (538)